X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with JUBILANT LIFE SCIENCES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs JUBILANT LIFE SCIENCES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA JUBILANT LIFE SCIENCES NATCO PHARMA/
JUBILANT LIFE SCIENCES
 
P/E (TTM) x 16.7 17.1 98.1% View Chart
P/BV x 18.0 4.5 402.1% View Chart
Dividend Yield % 0.6 0.4 156.5%  

Financials

 NATCO PHARMA   JUBILANT LIFE SCIENCES
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
JUBILANT LIFE SCIENCES
Mar-14
NATCO PHARMA/
JUBILANT LIFE SCIENCES
5-Yr Chart
Click to enlarge
High Rs877187 469.5%   
Low Rs42465 650.5%   
Sales per share (Unadj.) Rs223.4364.3 61.3%  
Earnings per share (Unadj.) Rs31.16.8 453.8%  
Cash flow per share (Unadj.) Rs40.324.5 164.4%  
Dividends per share (Unadj.) Rs5.003.00 166.7%  
Dividend yield (eoy) %0.82.4 32.3%  
Book value per share (Unadj.) Rs219.5164.9 133.1%  
Shares outstanding (eoy) m33.07159.28 20.8%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.90.3 841.9%   
Avg P/E ratio x20.918.4 113.8%  
P/CF ratio (eoy) x16.15.1 314.1%  
Price / Book Value ratio x3.00.8 387.9%  
Dividend payout %16.143.8 36.7%   
Avg Mkt Cap Rs m21,50420,061 107.2%   
No. of employees `000NA6.2 0.0%   
Total wages/salary Rs m1,12811,052 10.2%   
Avg. sales/employee Rs ThNM9,383.0-  
Avg. wages/employee Rs ThNM1,786.9-  
Avg. net profit/employee Rs ThNM176.3-  
INCOME DATA
Net Sales Rs m7,38958,034 12.7%  
Other income Rs m167191 87.7%   
Total revenues Rs m7,55658,224 13.0%   
Gross profit Rs m1,7935,786 31.0%  
Depreciation Rs m3042,812 10.8%   
Interest Rs m3663,237 11.3%   
Profit before tax Rs m1,290-72 -1,788.9%   
Minority Interest Rs m46-286 -16.2%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m02,145 0.0%   
Tax Rs m309696 44.3%   
Profit after tax Rs m1,0271,090 94.2%  
Gross profit margin %24.310.0 243.4%  
Effective tax rate %23.9-965.9 -2.5%   
Net profit margin %13.91.9 740.0%  
BALANCE SHEET DATA
Current assets Rs m3,68129,280 12.6%   
Current liabilities Rs m3,12338,912 8.0%   
Net working cap to sales %7.6-16.6 -45.5%  
Current ratio x1.20.8 156.7%  
Inventory Days Days8984 106.1%  
Debtors Days Days5951 115.8%  
Net fixed assets Rs m7,68555,712 13.8%   
Share capital Rs m331155 214.0%   
"Free" reserves Rs m6,67020,968 31.8%   
Net worth Rs m7,25926,265 27.6%   
Long term debt Rs m95517,169 5.6%   
Total assets Rs m11,95788,606 13.5%  
Interest coverage x4.51.0 462.5%   
Debt to equity ratio x0.10.7 20.1%  
Sales to assets ratio x0.60.7 94.3%   
Return on assets %11.74.9 238.6%  
Return on equity %14.24.2 340.9%  
Return on capital %20.711.6 179.2%  
Exports to sales %39.437.8 104.1%   
Imports to sales %5.716.5 34.6%   
Exports (fob) Rs m2,90821,933 13.3%   
Imports (cif) Rs m4219,567 4.4%   
Fx inflow Rs m3,44522,004 15.7%   
Fx outflow Rs m70311,749 6.0%   
Net fx Rs m2,74310,255 26.7%   
CASH FLOW
From Operations Rs m1,4408,026 17.9%  
From Investments Rs m-1,089-1,744 62.4%  
From Financial Activity Rs m-353-4,447 7.9%  
Net Cashflow Rs m-11,834 -0.1%  

Share Holding

Indian Promoters % 52.0 45.6 114.1%  
Foreign collaborators % 1.5 3.5 42.0%  
Indian inst/Mut Fund % 7.8 8.7 90.1%  
FIIs % 16.6 21.2 78.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 21.1 123.2%  
Shareholders   25,395 23,815 106.6%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SANOFI INDIA  TORRENT PHARMA  STRIDES SHASUN LTD  CIPLA  ABBOTT INDIA  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 93.3% YoY). Sales on the other hand came in at Rs 5 bn (up 21.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (1QFY19); Net Profit Up 39.4% (Quarterly Result Update)

Jul 31, 2018 | Updated on Jul 31, 2018

For the quarter ended June 2018, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (up 39.4% YoY). Sales on the other hand came in at Rs 21 bn (up 30.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 21, 2018 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS